Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...

GuruFocus.com11-08

Rytelo Net Product Revenue: $28.2 million in the first full quarter of U.S. sales. Total Net Revenue: $28.3 million for Q3 2024. Cash and Marketable Securities: Approximately $542.4 million on a pro ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481103987?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/00GoUv6CquqN1seUbxq.0A--~B/aD05OTt3PTE4MzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/fbb0a38c8039bad2b1a165db7b8b267a","is_english":true,"pubTime":"2024-11-08 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481103987","market":"us","top_or_hot":-1,"title":"Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...","media":"GuruFocus.com","content":"<div>\n<p>Rytelo Net Product Revenue: $28.2 million in the first full quarter of U.S. sales.\nTotal Net Revenue: $28.3 million for Q3 2024.\nCash and Marketable Securities: Approximately $542.4 million on a pro ...</p>\n\n<a href=\"https://finance.yahoo.com/news/geron-corp-gern-q3-2024-130041252.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/geron-corp-gern-q3-2024-130041252.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rytelo Net Product Revenue: $28.2 million in the first full quarter of U.S. sales.\nTotal Net Revenue: $28.3 million for Q3 2024.\nCash and Marketable Securities: Approximately $542.4 million on a pro ...</p>\n\n<a href=\"https://finance.yahoo.com/news/geron-corp-gern-q3-2024-130041252.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GERN","symbol_name":"杰龙","start_time":0,"source_url":"https://finance.yahoo.com/news/geron-corp-gern-q3-2024-130041252.html","article_id":"2481103987","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/00GoUv6CquqN1seUbxq.0A--~B/aD05OTt3PTE4MzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/fbb0a38c8039bad2b1a165db7b8b267a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481103987","pubTimestamp":1731070841,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Rytelo Net Product Revenue: $28.2 million in the first full quarter of U.S. sales.Total Net Revenue: $28.3 million for Q3 2024.Cash and Marketable Securities: Approximately $542.4 million on a pro forma basis as of September 30, 2024.Total Operating Expenses: $56.5 million for Q3 2024.Research and Development Expenses: $20.2 million for Q3 2024.Selling, General, and Administrative Expenses: $35.9 million for Q3 2024.Cost of Goods Sold: Approximately $450,000 for Q3 2024.Debt Financing and Royalty Transactions: $250 million in gross proceeds from a synthetic royalty transaction and debt financing.Projected Operating Expenses for FY 2024: Expected to be in the range of $260 million to $270 million.GuruFocus has detected 5 Warning Signs with GERN.Geron Corp  achieved $28.2 million in Rytelo net product revenue in its first full quarter, exceeding expectations.Geron Corp  completed a synthetic royalty transaction and a debt financing transaction, generating $250 million in gross proceeds.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GERN":"杰龙"},"translate_title":"Geron Corp(GERN)2024年第三季度收益看涨期权亮点：Rytelo的强劲推出和战略……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":1},"content_text":"Rytelo Net Product Revenue: $28.2 million in the first full quarter of U.S. sales.\nTotal Net Revenue: $28.3 million for Q3 2024.\nCash and Marketable Securities: Approximately $542.4 million on a pro forma basis as of September 30, 2024.\nTotal Operating Expenses: $56.5 million for Q3 2024.\nResearch and Development Expenses: $20.2 million for Q3 2024.\nSelling, General, and Administrative Expenses: $35.9 million for Q3 2024.\nCost of Goods Sold: Approximately $450,000 for Q3 2024.\nDebt Financing and Royalty Transactions: $250 million in gross proceeds from a synthetic royalty transaction and debt financing.\nProjected Operating Expenses for FY 2024: Expected to be in the range of $260 million to $270 million.\n\n\nWarning! GuruFocus has detected 5 Warning Signs with GERN.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nGeron Corp (NASDAQ:GERN) achieved $28.2 million in Rytelo net product revenue in its first full quarter, exceeding expectations.\nThe company has a strong intellectual property position, with exclusivity in the U.S. through August 2037 for Rytelo.\nGeron Corp (NASDAQ:GERN) completed a synthetic royalty transaction and a debt financing transaction, generating $250 million in gross proceeds.\nThe company has achieved significant payer coverage for Rytelo, with policies covering approximately 70% of U.S. covered lives.\nGeron Corp (NASDAQ:GERN) is preparing for potential EU commercialization of Rytelo, with expected approval in the first half of 2025.\n\n Negative Points \n\nThe company faces potential fluctuations in weekly sales data, which may not fully capture internal insights.\nGeron Corp (NASDAQ:GERN) is still in the early stages of Rytelo's launch, with potential variability in growth trajectory.\nThe company has significant operating expenses, with total operating expenses for the nine months ended September 30, 2024, at $183.1 million.\nThere is a dependency on achieving internal revenue projections to reach break-even without additional financing.\nThe company is facing competition in the first-line treatment setting from other therapies like luspatercept.\n\n Q & A Highlights \nQ: Can you provide insights on how you expect growth cadence to look over the next few quarters, and how your growth assumptions factored into the terms of the royalty deal? A: Jim Ziegler, Executive Vice President, Chief Commercial Officer, stated that they expect steady, consistent growth across all patient segments, particularly in second line and third line plus patients. Michelle Robertson, Chief Financial Officer, explained that the royalty deal was negotiated using their current internal forecasts, and they are pleased with the competitive terms achieved.\nQ: Can you clarify how investors should think about the royalty rate and cap multiplier, and your cash flow expectations? A: Michelle Robertson noted that the royalty rate is competitive and emphasized the focus on the cap of 1.65 times the closing payment. She mentioned that based on their current plans, they could reach break-even without needing additional financing, maintaining a 12-month cash buffer.\nQ: What does \"steady growth\" mean in terms of patient growth or growth rate, and what portion of patients have previously seen treatment with Revil? A: Jim Ziegler explained that they expect growth across all patient segments in both academic and community settings. They are seeing uptake and utilization across all patient segments, including first line ESA ineligible, second line, and third line patients.\nQ: Can you discuss the initial real-world experience in terms of benefit on transfusion reductions and safety profile? A: Jim Ziegler stated that real-world experiences are consistent with clinical trials, although it is still early in the launch. He noted that they expect their differentiated product profile to allow them to become standard of care in second line.\nQ: Can you elaborate on why the royalty and debt structure was chosen over a simpler equity raise? A: Michelle Robertson explained that the hybrid structure was chosen for flexibility, allowing them to pay off existing debt and retain more sales during the early launch period. This approach reduces dependency on equity markets and avoids further stock dilution.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481103987"}